<DOC>
	<DOCNO>NCT00354809</DOCNO>
	<brief_summary>This study design determine whether morning dos GW679769 , take daily 1 9 day , promote sleep follow night without significant post-dose thinking impairment drowsiness subject primary insomnia .</brief_summary>
	<brief_title>Evaluation A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criterion : Difficulty go sleep and/or stay asleep least past 3 month . Insomnia must result significant distress impairment function home , socially work . Otherwise good health significant unstable medical disorder include psychiatric , neurological , endocrine , heart , lung gastrointestinal disorder , drug/alcohol abuse , cognitive impairment , cancer chronic pain condition arthritis . Exclusion criterion : History sleep disorder sleep apnea restless leg syndrome ; regular sleep habit , include bedtime 9 PM midnight , nightshift/rotating shift work , frequent napping plan travel across &gt; 2 time zone . Use moderate use nicotine , caffeine alcoholic product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>cognition</keyword>
	<keyword>Primary Insomnia</keyword>
	<keyword>sleep</keyword>
	<keyword>polysomnography</keyword>
</DOC>